Skip to main content

Endometrial Hyperplasia

4
Pipeline Programs
4
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bayer
MIRENAApproved
levonorgestrel
Bayer
Progestin [EPC]intrauterine2000
777K Part D

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
MIRENA(BAY865028)Phase 3
Pfizer
PfizerNEW YORK, NY
2 programs
2
Bazedoxifene/Conjugate EstrogensPhase 31 trial
Bazedoxifene/Conjugated EstrogenPhase 31 trial
Active Trials
NCT00675688Completed3,544Est. Jan 2006
NCT00242710Completed1,083Est. Sep 2008
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
SemaglutidePHASE_2Peptide1 trial
Active Trials
NCT05829460Withdrawn0Est. Apr 2032
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
progesteronePHASE_21 trial
Active Trials
NCT00919919Unknown60Est. Nov 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerBazedoxifene/Conjugated Estrogen
PfizerBazedoxifene/Conjugate Estrogens
Novo NordiskSemaglutide
Ferring Pharmaceuticalsprogesterone

Clinical Trials (4)

Total enrollment: 4,687 patients across 4 trials

NCT00242710PfizerBazedoxifene/Conjugated Estrogen

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Start: Sep 2005Est. completion: Sep 20081,083 patients
Phase 3Completed
NCT00675688PfizerBazedoxifene/Conjugate Estrogens

Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Start: Apr 2002Est. completion: Jan 20063,544 patients
Phase 3Completed

Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Start: Mar 2025Est. completion: Apr 20320
Phase 2Withdrawn

Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen

Start: Jun 2009Est. completion: Nov 201060 patients
Phase 2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.